Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pileri

Showing results (771-780 of 992) with videos related to

Pageof 100
Sort By:
International Journal of Cancer|May 4, 2013
Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseasesMichele Bernasconi, Seigo Ueda, Patricia Krukowski, et al.
International Journal of Clinical & Laboratory Research|August 5, 1998
The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapyF Dammacco, F Silvestris, G L Castoldi, et al.
Blood|June 22, 2007
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trialAndrea Gallamini, Francesco Zaja, Caterina Patti, et al.
The Journal of Pathology|July 20, 2004
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformationCristiana Bellan, Giulia De Falco, Stefano Lazzi, et al.
BMC Cancer|October 11, 2015
Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulationGiulia De Falco, Maria Raffaella Ambrosio, Fabio Fuligni, et al.
Leukemia|December 26, 2001
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphomaM Ladetto, F Zallio, S Vallet, et al.
British Journal of Cancer|June 22, 2016
FAT1: a potential target for monoclonal antibody therapy in colon cancerPiero Pileri, Susanna Campagnoli, Alberto Grandi, et al.
Blood|April 4, 2008
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectKerry J Savage, Nancy Lee Harris, Julie M Vose, et al.
Oncology Reports|November 6, 2007
Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphomaGianluca Brusa, Elisa Zuffa, Claudia Maria Hattinger, et al.
Cancers|September 28, 2021
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2)Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, et al.
Pageof 100

Showing results (771-780 of 992) with videos related to

Sort By:
Pageof 100
International Journal of Cancer|May 4, 2013
Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseasesMichele Bernasconi, Seigo Ueda, Patricia Krukowski, et al.
International Journal of Clinical & Laboratory Research|August 5, 1998
The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapyF Dammacco, F Silvestris, G L Castoldi, et al.
Blood|June 22, 2007
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trialAndrea Gallamini, Francesco Zaja, Caterina Patti, et al.
The Journal of Pathology|July 20, 2004
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformationCristiana Bellan, Giulia De Falco, Stefano Lazzi, et al.
BMC Cancer|October 11, 2015
Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulationGiulia De Falco, Maria Raffaella Ambrosio, Fabio Fuligni, et al.
Leukemia|December 26, 2001
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphomaM Ladetto, F Zallio, S Vallet, et al.
British Journal of Cancer|June 22, 2016
FAT1: a potential target for monoclonal antibody therapy in colon cancerPiero Pileri, Susanna Campagnoli, Alberto Grandi, et al.
Blood|April 4, 2008
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectKerry J Savage, Nancy Lee Harris, Julie M Vose, et al.
Oncology Reports|November 6, 2007
Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphomaGianluca Brusa, Elisa Zuffa, Claudia Maria Hattinger, et al.
Cancers|September 28, 2021
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2)Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, et al.
Pageof 100